XML 53 R36.htm IDEA: XBRL DOCUMENT v3.25.0.1
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Schedule of Cash and Cash Equivalents
The following is a summary of cash, cash equivalents and restricted cash on the consolidated balance sheets (in thousands):
December 31,
2024		December 31,
2023
Cash$32,251 $22,407 
U.S. Treasury4,743 — 
Money market funds61,722 144,892 
Restricted cash29 331 
Total cash, cash equivalents and restricted cash as presented on the consolidated statements of cash flows$98,745 $167,630 
Restrictions on Cash and Cash Equivalents
The following is a summary of cash, cash equivalents and restricted cash on the consolidated balance sheets (in thousands):
December 31,
2024		December 31,
2023
Cash$32,251 $22,407 
U.S. Treasury4,743 — 
Money market funds61,722 144,892 
Restricted cash29 331 
Total cash, cash equivalents and restricted cash as presented on the consolidated statements of cash flows$98,745 $167,630 
Schedule of Accounts Receivable, Allowance for Doubtful Debt
The changes in the allowance for credit losses for the year ended December 31, 2024 were as follows (in thousands):
Allowance for credit losses
Balance at December 31, 2022$102 
Cumulative effect adjustment upon adoption of ASU 2016-13— 
Balance at January 1, 2023102 
Utilization of allowance for credit losses— 
Provision for credit losses270 
Balance at December 31, 2023$372 
Utilization of allowance for credit losses(197)
Provision for credit losses135 
Balance at December 31, 2024$310 
Schedule of Useful Life of Property Plant and Equipment The Company’s estimated useful lives of its property and equipment are as follows:
Estimated Useful Lives
Building20 years
Furniture and fixtures7 years
Laboratory equipment5 years
Office and computer equipment3 years
Leasehold improvementsShorter of expected lease term or estimated useful life
Schedule of Finite-Lived Intangible Assets The Company’s estimated useful lives of its intangible assets are as follows:
Estimated Useful Lives
Patent20 years
Trademarks10 years
Trade name
2 - 15 years
FCI developed technology
1 - 6 years
Customer relationship
7 - 9 years
Reagent licenses7 years
IP license5 years